These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27866832)

  • 41. [Lysosomal storage diseases in selected clinical cases].
    Banyś A; Ostróżka-Cieślik A; Sarecka-Hujar B
    Wiad Lek; 2016; 69(1):43-7. PubMed ID: 27162295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
    Valayannopoulos V
    Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
    Benedik-Dolničar M; Kitanovski L
    Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Memories of John N. Brady: scientist, mentor and friend.
    Pise-Masison CA; Marriott SJ
    Retrovirology; 2009 May; 6():48. PubMed ID: 19454030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy for lysosomal storage disorders.
    Beck M
    IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The blood-brain barrier and neurodegenerative lysosomal storage diseases].
    Urayama A
    Brain Nerve; 2013 Feb; 65(2):153-63. PubMed ID: 23399673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment for Lsds: real options for several diseases. Forward.
    Cohen IJ; Baris HN; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():71. PubMed ID: 25345087
    [No Abstract]   [Full Text] [Related]  

  • 49. Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells.
    Monestime G; Borger DK; Kim J; Lopez G; Allgaeuer M; Jain D; Vortmeyer A; Wang HW; Sidransky E
    Mol Genet Metab; 2016 May; 118(1):55-9. PubMed ID: 26992326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.
    Barranger JA; Brady RO; Grabowski GA; Mankin H; Mistry PK; Weinreb NJ
    Am J Hematol; 2014 May; 89(5):457-8. PubMed ID: 24488939
    [No Abstract]   [Full Text] [Related]  

  • 51. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases.
    Pchelina SN; Nuzhnyi EP; Emelyanov AK; Boukina TM; Usenko TS; Nikolaev MA; Salogub GN; Yakimovskii AF; Zakharova EY
    Neurosci Lett; 2014 Nov; 583():188-93. PubMed ID: 25265039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [How does the landscape change in lysosomal storage disease].
    Parini R
    Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
    [No Abstract]   [Full Text] [Related]  

  • 53. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
    Camou F; Viallard JF
    Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
    [No Abstract]   [Full Text] [Related]  

  • 55. Novel therapies and future perspectives.
    Scarpa M; Frustaci A
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S109-10. PubMed ID: 20040320
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gaucher's disease: the changing paradigm of a lysosomal disorder.
    Mehta A
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():3-5. PubMed ID: 22230118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
    Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
    Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
    Elstein D; Abrahamov A; Oz A; Arbel N; Baris H; Zimran A
    Blood Cells Mol Dis; 2015 Dec; 55(4):415-8. PubMed ID: 26460268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.